New Biomarkers and Therapeutic Targets in Osteoporosis Via Omics Technologies
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
AgeNot listed
SponsorNational and Kapodistrian University of Athens
About this trial
This study aims to discover novel biomarkers and therapeutic targets for osteoporosis through the use of advanced omics technologies, including proteomics and metabolomics. By analyzing bone and plasma samples from patients with osteoporosis, the research seeks to understand the underlying mechanisms of the disease and identify potential diagnostic and therapeutic biomarkers.
Eligibility criteria
Qualifiers
Postmenopausal Female Patients with osteoporotic subcapital femoral neck fracture (Arm 1)
Postmenopausal Female Patients with hip osteoarthritis that will undergo Total Hip Replacement (Arm 2)
Disqualifiers
Patients that have undergone before osteoporotic fractures
Patients with severe cardiovascular, pulmonary, autoimmune, or urinary system conditions
Trial design
Treatments tested in this trial
- Bone, Serum and Plasma sample
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
National and Kapodistrian University of Athens
Lead sponsor
National Hellenic Research Foundation
Collaborator
Source ClinicalTrials.gov